Philipp Mathieu appointed CEO of Immunovia AB
LUND, Sweden, June 2, 2022 /PRNewswire/ — Immunovia today announced that Philippe Matthew was appointed CEO and Chairman effective immediately. Since January, Philipp has been acting CEO and President.
Commenting on the announcement, Carl Borrebaeck, Chairman, said: “After carefully evaluating the external candidates, the Board of Directors has decided that Philipp, with his extensive experience and financial knowledge, is the right person to lead Immunovia during the transition from a research-based company to a successful commercial enterprise. While serving as interim CEO, Philipp demonstrated effective leadership and quickly advanced the company’s strategic priorities. Immunovia is now well positioned for the commercial deployment of early detection of pancreatic cancer with its pioneering IMMray™ PanCan-d test system in the United States.”
“I am honored and excited to continue to lead our outstanding team through this important phase in Immunovia’s evolution. Immunovia is at the forefront of revolutionizing the early detection of pancreatic cancer and addressing a huge unmet medical need, which is a hugely motivating mission,” says Philippe MatthewCEO and President of Immunovia.
Philippe Matthew has extensive experience advising on corporate strategy, mergers and acquisitions and capital markets transactions to companies in the healthcare and life sciences sector. Most recently, Philipp was a portfolio manager and advisor to a multinational family office. Previously, he was an investment banker specializing in the healthcare sector at Lazard and Lehman Brothers.
For more information please contact:
CEO and President
E-mail: [email protected]
Senior Director of Investor Relations and Corporate Communications
E-mail: [email protected]
Tel: +46 736 36 35 74
This is information that Immunovia is required to make public under the EU Market Abuse Regulation. The information has been submitted for publication, through the contact person listed above, to 08:30 CET June 2, 2022.
Immunovia AB is a diagnostics company with a vision to revolutionize blood diagnostics and increase survival rates for cancer patients.
Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unparalleled clinical performance. Commercialization of IMMray™ PanCan-d began in August 2021 in the UNITED STATES and IMMray™ PanCan-d is offered as a laboratory-developed test (LDT) exclusively by Immunovia, Inc. For more information, see: www.immunoviainc.com.
Immunovia is collaborating and engaging with healthcare providers, leading experts and patient advocacy groups around the world to make this test available to all high-risk pancreatic cancer groups.
The UNITED STATESthe first market in which IMMray™ PanCan-d is commercially available, is the world’s largest market for the detection of pancreatic cancer with an estimated value of more than $4 billion annually.
Immunovia (IMMNOV) shares are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Immunovia AB